Stryker Aktie News

There are two types of Halloween people: those who like jump scares and those who don't. But even if you're a fan of haunted hayrides and movies like The Conjuring, you probably don't want to ever get a jump scare from your portfolio, which is why so many investors use diversified index funds with the bulk of their wealth.

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.

PORTAGE, Mich.--(BUSINESS WIRE)--Stryker will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association Annual Meeting, October 15–18, in Phoenix, Ariz.

Portage, Michigan, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its third quarter of fiscal year 2025 on Thursday, October 30, 2025.  A press release will be issued at approximately 4:05 p.m.

PORTAGE, Mich.--(BUSINESS WIRE)--Stryker will launch its Incompass™ Total Ankle System at the 2025 AOFAS Annual Meeting in Savannah, Georgia, September 10–13, 2025 (booth # 401).

Stryker Corporation (NYSE:SYK ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 2:15 PM EDT Company Participants Jason Beach - Vice President of Finance & Investor Relations J. Pierce - Group President of MedSurg & Neurotechnology Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device ...

I reiterate a Hold rating on Stryker Corporation, with a fair value of $382 per share, despite recent strong quarterly results. Stryker's Mako installations and utilization remain robust, and upcoming Mako Spine and shoulder launches are on track to drive future growth. SYK management is focused on margin expansion through supply chain efficiencies, but cost synergies from past acquisitions rem...

Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Recent quarterly results beat expectations, driven by robust performance across the business and ongoing market share gains. Management remains focused on growth and margin optimization, with M&A and innovation — especially in robotics and neuromodulation — central to the strat...